



## Clinical trial results:

**Double blinded, randomized, Priorix®- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers**

### Summary

EudraCT number	2015-004037-26
Trial protocol	DE AT
Global end of trial date	16 April 2018

### Results information

Result version number	v1
This version publication date	09 February 2020
First version publication date	09 February 2020

### Trial information

#### Trial identification

Sponsor protocol code	MV-CHIK-202
-----------------------	-------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02861586
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Themis Bioscience GmbH
Sponsor organisation address	Muthgasse 11/2, Vienna, Austria, 1190
Public contact	Andrea Pfeiffer, MSc Clinica Project Officer, Themis Bioscience GmbH, +43 6765102835, andrea.pfeiffer@themisbio.com
Scientific contact	Dr. Katrin Ramsauer Chief Scientific Officer, Themis Bioscience GmbH, +43 676843496418, katrin.ramsauer@themisbio.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	17 July 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	16 April 2018
Global end of trial reached?	Yes
Global end of trial date	16 April 2018
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To investigate the immunogenicity and safety of MV-CHIK 28 days after primary immunization regime, comprising one or two vaccinations.

Protection of trial subjects:

Subjects' safety was an essential concern in this clinical study MV-CHIK-202 and was addressed in the clinical study protocol:

-Physical examination: During each study visit subjects underwent a symptom-directed physical examination and the assessment of vital signs like systolic and diastolic blood pressure, pulse and body temperature, allowed to detect and record adverse conditions.

-Post vaccination reactogenicity assessment: All subjects were observed for 1 hour after each vaccination in order to investigate local and systemic tolerability and to ensure the subjects wellbeing before discharge.

-AEs: For general safety reasons, all subjects that at least received one vaccination were followed up for at least 28 days after the last vaccination.

-Body temperature: All subjects received a thermometer and were asked to note their daily body temperature in a diary for 7 days after each vaccination to perceive side effects.

-Subject diary: Solicited AEs were recorded by the subjects by checking the presence of listed symptoms in a subject's diary. The diary provided also space for noting unsolicited AEs and concomitant medication. This enabled the subjects to better remember AEs and the investigator to gather and assess AEs in more detail.

-Laboratory parameters: were regularly measured to reveal clinically relevant lab values on hematology, blood chemistry, coagulation parameters and urinalysis. All lab results were evaluated carefully by the investigator to identify adverse conditions.

-Safety stopping rules: An independent DSMB was installed to review safety information, and if necessary, to determine whether study or individual subject stopping rules have been met.

-Data Safety Monitoring Board (DSMB): In close cooperation with the DSMB and the investigators the protection of study participants was assured.

Background therapy:

n.a.

Evidence for comparator:

Priorix® (Glaxo Smith Kline GSK) a measles, mumps, rubella vaccine was used as a control-vaccine because the contained attenuated Schwarz measles virus strain is the same strain, used as backbone in MV-CHIK.

Actual start date of recruitment	17 August 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Austria: 168
Country: Number of subjects enrolled	Germany: 95

Worldwide total number of subjects	263
EEA total number of subjects	263

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	263
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

First subject in, Austria: 17-Aug-2016

Last subject out, Austria: 11-Jan-2018

First subject in, Germany: 04-May-2017

Last subject out, Germany: 16-Apr-2018

### Pre-assignment

Screening details:

To confirm the health status of volunteers the following data and parameters were assessed during screening:

Medical/vaccination history, physical examination, hematology, coagulation parameters, HIV, hepatitis B/C, urinalysis

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Assessor

Blinding implementation details:

This study was conducted in a double-blind manner in regard to assignment to Treatment Groups A, B, C or D.

An assignment to the measles booster groups M1 and M2 was apparent to both, subject and study personnel, but the vaccination sequence was kept double-blind (allocation to M1 or to M2 was unknown).

Vaccine was prepared by authorized unblinded personnel otherwise not involved in the conduct of the study. Ready prepared syringes were blinded.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Treatment Group A

Arm description:

Treatment group A received i.m. vaccinations with MV-CHIK low dose ( $5 \times 10^4$  ( $\pm 0.5$  log) TCID<sub>50</sub> per 0.3 mL) on study day 0 and 28, placebo on day 196.

Arm type	Experimental
Investigational medicinal product name	MV-CHIK low dose $5 \times 10^4$ ( $\pm 0.5$ log) TCID <sub>50</sub> /dose
Investigational medicinal product code	MV-CHIK
Other name	Chikungunya vaccine
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Treatment group A received i.m. vaccinations with 0.3 ml MV-CHIK low dose on study day 0 and 28, and 0.3 ml placebo on day 196.

Investigational medicinal product name	Placebo NaCl 0.9%
Investigational medicinal product code	Placebo
Other name	Physiological saline solution
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Treatment group A received i.m. vaccinations with 0.3 ml MV-CHIK low dose on study day 0 and 28, and 0.3 ml placebo on day 196.

<b>Arm title</b>	Treatment Group B
------------------	-------------------

**Arm description:**

Group B subjects received i.m. vaccinations with placebo on study day 0; MV-CHIK low dose (5x10E4 ( $\pm$  0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.

Arm type	Experimental
Investigational medicinal product name	MV-CHIK low dose 5x10E4 ( $\pm$ 0.5 log) TCID50/ dose
Investigational medicinal product code	MV-CHIK
Other name	Chikungunya vaccine
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Group B subjects received i.m. vaccinations with 0.3 ml placebo on study day 0, and 0.3 ml MV-CHIK low dose on day 28 and on day 196.

Investigational medicinal product name	Placebo NaCl 0.9%
Investigational medicinal product code	Placebo
Other name	physiological saline solution
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Group B subjects received i.m. vaccinations with 0.3 ml placebo on study day 0, and 0.3 ml MV-CHIK low dose on day 28 and on day 196.

<b>Arm title</b>	Treatment Group C
------------------	-------------------

**Arm description:**

Group C received i.m. vaccinations with MV-CHIK high dose (5x10E5 ( $\pm$  0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.

Arm type	Experimental
Investigational medicinal product name	MV-CHIK high dose 5x10E5 ( $\pm$ 0.5 log) TCID50/ dose
Investigational medicinal product code	MV-CHIK
Other name	Chikungunya vaccine
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intranasal use

**Dosage and administration details:**

Group C received i.m. vaccinations with 0.3 ml MV-CHIK high dose on study day 0 and 28, and 0.3 ml placebo on day 196.

Investigational medicinal product name	Placebo NaCl 0.9%
Investigational medicinal product code	Placebo
Other name	Physiological saline solution
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

Group C received i.m. vaccinations with 0.3 ml MV-CHIK high dose on study day 0 and 28, and 0.3 ml placebo on day 196.

<b>Arm title</b>	Treatment Group D
------------------	-------------------

**Arm description:**

Group D received i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5x10E5 ( $\pm$  0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.

Arm type	Experimental
Investigational medicinal product name	MV-CHIK high dose 5x10E5 ( $\pm$ 0.5 log) TCID50/ dose
Investigational medicinal product code	MV-CHIK
Other name	Chikungunya vaccine
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intranasal use

**Dosage and administration details:**

Group D received i.m. vaccinations with 0.3 ml placebo on study day 0, and 0.3 ml MV-CHIK high dose

on study day 28 and on day 196.

Investigational medicinal product name	Placebo NaCl 0.9%
Investigational medicinal product code	Placebo
Other name	Physiological saline solution
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Group D received i.m. vaccinations with 0.3 ml placebo on study day 0, and 0.3 ml MV-CHIK high dose on study day 28 and on day 196.

<b>Arm title</b>	Treatment Group M1
------------------	--------------------

Arm description:

Measles Booster Group 1, M1: received i.m. vaccinations with Priorix® 28 days prior to vaccination with MV-CHIK on day 0 and 28, and placebo on day 168 and 196.

Arm type	Experimental
Investigational medicinal product name	Priorix® measles, mumps rubella vaccine
Investigational medicinal product code	Priorix® controll vaccine
Other name	comperator
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Subjects of group M1 received the control vaccine (Priorix®) 28 days prior to two MV-CHIK vaccinations on day 0 and 28, followed by two placebo injections on day 168 and 196.

<b>Arm title</b>	Treatment Group M2
------------------	--------------------

Arm description:

Measles Booster Group 2, M2: received i.m. vaccinations with Priorix® 28 days prior to placebo on day 0 and 28, and MV-CHIK on day 168 and 196.

Arm type	Experimental
Investigational medicinal product name	Priorix® measles, mumps, rubella vaccine
Investigational medicinal product code	Priorix®controll vaccine
Other name	comperator
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Group M2 received the control vaccine (Priorix®) 28 days prior to two placebo injections on day 0 and 28, followed by two MV-CHIK vaccinations on day 168 and 196.

<b>Arm title</b>	Control Group CV1, A/C
------------------	------------------------

Arm description:

Control Group CV1, A/C received i.m. vaccinations with Priorix® on study day 0 and 28, and placebo on day 196.

Arm type	Active comparator
Investigational medicinal product name	Priorix® measles, mumps, rubella vaccine
Investigational medicinal product code	Priorix® control vaccine
Other name	comperator
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Control Group CV1, A/C received i.m. vaccinations with Priorix® on study day 0 and 28, and placebo on day 196.

Investigational medicinal product name	Placebo NaCl 0.9%
Investigational medicinal product code	Placebo
Other name	Physiological saline solution
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Control Group CV1, A/C received i.m. vaccinations with Priorix® on study day 0 and 28, and placebo on day 196.

<b>Arm title</b>	Control Group CV2, B/D
Arm description: Control Group CV2, B/D received i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.	
Arm type	Active comparator
Investigational medicinal product name	Priorix® measles, mumps, rubella vaccine
Investigational medicinal product code	Priorix® control vaccine
Other name	comperator
Pharmaceutical forms	Powder and solvent for solution for injection/skin-prick test
Routes of administration	Intramuscular use

Dosage and administration details:

Control Group CV2, B/D received i.m. vaccinations with placebo on study day 0, and Priorix® on day 28 and day 196.

Investigational medicinal product name	Placebo NaCl 0.9%
Investigational medicinal product code	Placebo
Other name	Physiological saline solution
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Control Group CV2, B/D received i.m. vaccinations with placebo on study day 0, and Priorix® on day 28 and day 196.

<b>Number of subjects in period 1</b>	Treatment Group A	Treatment Group B	Treatment Group C
Started	51	47	47
Completed	49	44	47
Not completed	2	3	0
Consent withdrawn by subject	1	2	-
Adverse event, non-fatal	-	-	-
Lost to follow-up	1	1	-

<b>Number of subjects in period 1</b>	Treatment Group D	Treatment Group M1	Treatment Group M2
Started	50	18	16
Completed	44	16	15
Not completed	6	2	1
Consent withdrawn by subject	2	1	-
Adverse event, non-fatal	1	-	-
Lost to follow-up	3	1	1

<b>Number of subjects in period 1</b>	Control Group CV1, A/C	Control Group CV2, B/D
Started	18	16

Completed	16	16
Not completed	2	0
Consent withdrawn by subject	-	-
Adverse event, non-fatal	-	-
Lost to follow-up	2	-

## Baseline characteristics

---

### Reporting groups

---

Reporting group title	overall trial
-----------------------	---------------

---

Reporting group description: -

<b>Reporting group values</b>	overall trial	Total	
Number of subjects	263	263	
Age categorical			
study population: healthy male and female volunteers aged 18 -55 years			
Units: Subjects			
18-55	263	263	
Gender categorical			
Units: Subjects			
Female	140	140	
Male	123	123	

## End points

### End points reporting groups

Reporting group title	Treatment Group A
Reporting group description: Treatment group A received i.m. vaccinations with MV-CHIK low dose ( $5 \times 10^4$ ( $\pm 0.5$ log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.	
Reporting group title	Treatment Group B
Reporting group description: Group B subjects received i.m. vaccinations with placebo on study day 0; MV-CHIK low dose ( $5 \times 10^4$ ( $\pm 0.5$ log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.	
Reporting group title	Treatment Group C
Reporting group description: Group C received i.m. vaccinations with MV-CHIK high dose ( $5 \times 10^5$ ( $\pm 0.5$ log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.	
Reporting group title	Treatment Group D
Reporting group description: Group D received i.m. vaccinations with placebo on study day 0, MV-CHIK high dose ( $5 \times 10^5$ ( $\pm 0.5$ log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.	
Reporting group title	Treatment Group M1
Reporting group description: Measles Booster Group 1, M1: received i.m. vaccinations with Priorix® 28 days prior to vaccination with MV-CHIK on day 0 and 28, and placebo on day 168 and 196.	
Reporting group title	Treatment Group M2
Reporting group description: Measles Booster Group 2, M2: received i.m. vaccinations with Priorix® 28 days prior to placebo on day 0 and 28, and MV-CHIK on day 168 and 196.	
Reporting group title	Control Group CV1, A/C
Reporting group description: Control Group CV1, A/C received i.m. vaccinations with Priorix® on study day 0 and 28, and placebo on day 196.	
Reporting group title	Control Group CV2, B/D
Reporting group description: Control Group CV2, B/D received i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.	
Subject analysis set title	Modified Intent-to-Treat Population
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: The exploratory immunogenicity analyses were based on the modified Intent-to-treat (mITT) population. The mITT population included all randomized subjects who received at least one vaccination. Subjects were analyzed according to the treatment group they were randomized to, rather than by the actual treatment they received.	
Subject analysis set title	Per Protocol Population
Subject analysis set type	Per protocol
Subject analysis set description: The Per-Protocol (PP) population was defined as the mITT population minus subjects with at least one major protocol deviation. The PP population excluded an enrolled subject if one of the following criteria was met: Immunosuppressive drugs: Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to vaccination, or anticipated use during the trial Subjects with any confirmed immunosuppressive or immunodeficient condition, including HIV, hepatitis A, B or C infection or a family history of congenital or hereditary immunodeficiency Subjects who received the wrong or no study medication Subjects with other major protocol deviations	

## Primary: Immunogenicity on day 56 by PRNT50

End point title	Immunogenicity on day 56 by PRNT50
End point description:	Immunogenicity on study day 56 confirmed by the presence of functional anti-chikungunya antibodies as determined by the plaque reduction neutralization test (PRNT50)
End point type	Primary
End point timeframe:	Functional anti-chikungunya antibodies measured by the plaque reduction neutralization test (PRNT50) on study day 56

End point values	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	44	47	44
Units: Titer				
geometric mean (standard deviation)	50.2 ( $\pm$ 127.69)	12.9 ( $\pm$ 100.47)	174.8 ( $\pm$ 436.11)	33.6 ( $\pm$ 59.38)

End point values	Treatment Group M1	Treatment Group M2	Control Group CV1, A/C	Control Group CV2, B/D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	15	16	16
Units: Titer				
geometric mean (standard deviation)	80.0 ( $\pm$ 233.80)	5.0 ( $\pm$ 0.00)	5.0 ( $\pm$ 0.00)	5.0 ( $\pm$ 0.00)

## Statistical analyses

Statistical analysis title	ANOVA PRNT50 at Day 56
Statistical analysis description:	ANOVA with fixed factor treatment group for GMT of functional antibodies by PRNT50 at day 56.
Comparison groups	Treatment Group A v Treatment Group B v Treatment Group C v Treatment Group D v Treatment Group M1 v Treatment Group M2 v Control Group CV1, A/C v Control Group CV2, B/D
Number of subjects included in analysis	247
Analysis specification	Pre-specified
Analysis type	superiority
P-value	$\leq 0.05$
Method	ANOVA
Parameter estimate	Mean difference (final values)
Confidence interval	
level	95 %
sides	2-sided
Variability estimate	Standard deviation

## Secondary: Anti-measles antibodies by ELISA

End point title	Anti-measles antibodies by ELISA
End point description:	Measurement of anti-measles antibody titers on day 0, 28, and 56 and additionally for group M1 and M2 on day -28 as determined by ELISA. Please note that for some timepoints testing has not been done. "Not done" cannot be entered but only numerical values. "9999" should serve as indicator of a test which was not performed.
End point type	Secondary
End point timeframe:	Anti-measles antibodies on day 0, 28, and 56 and additionally for group M1 and M2 on day -28 as determined by ELISA

End point values	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	44	47	44
Units: Titer				
geometric mean (standard deviation)				
Day -28	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
Day 0	456.2 (± 1398.54)	398.1 (± 1267.55)	495.0 (± 1181.36)	401.8 (± 1073.54)
Day 28	1509.4 (± 1360.83)	396.9 (± 1183.04)	2343.9 (± 1357.29)	2343.9 (± 1357.29)
Day 56	1651.8 (± 1384.39)	1255.0 (± 1279.28)	2750.5 (± 1284.23)	2750.5 (± 1284.23)

End point values	Treatment Group M1	Treatment Group M2	Control Group CV1, A/C	Control Group CV2, B/D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	15	16	16
Units: Titer				
geometric mean (standard deviation)				
Day -28	542.6 (± 1118.52)	304.5 (± 343.53)	9999 (± 9999)	9999 (± 9999)
Day 0	785.6 (± 1149.47)	645.9 (± 850.56)	693.9 (± 1307.42)	390.4 (± 1106.86)
Day 28	1761.5 (± 1578.85)	561.2 (± 385.36)	1200.6 (± 1129.77)	447.5 (± 1139.37)
Day 56	1825.2 (± 1459.93)	521.4 (± 455.37)	1129.4 (± 1168.63)	673.8 (± 917.52)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Shedding (Urine)

End point title	Shedding (Urine) <sup>[1]</sup>
End point description:	Shedding of live recombinant virus until day 196 (in a subset of subjects at one site)
End point type	Secondary
End point timeframe:	Shedding of live recombinant virus on day 0, 7, 10, 14, 28 and day 196 after the first injection

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistic calculations were planned or performed - not one case of shedding was observed.

Shedding analysis relies on PCR methods amplifying measles sequences. As M1 and M2 groups receive a measles vaccination and the study vaccination (modified measles virus), a potential positive result would not be indicative of the reason and therefore these groups were not tested for shedding.

End point values	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	4
Units: Subjects shedding measles virus				
Day 0	0	0	0	0
Day 7	0	0	0	0
Day 10	0	0	0	0
Day 14	0	0	0	0
Day 28	0	0	0	0
Day 196	0	0	0	0

End point values	Control Group CV1, A/C	Control Group CV2, B/D		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	2		
Units: Subjects shedding measles virus				
Day 0	0	0		
Day 7	0	0		
Day 10	0	0		
Day 14	0	0		
Day 28	0	0		
Day 196	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Immunogenicity on days 0, 28, 196, and 224 (and 168 for M1 and M2) by PRNT50

End point title	Immunogenicity on days 0, 28, 196, and 224 (and 168 for M1
-----------------	--

## End point description:

Immunogenicity on days 0, 28, 196 and 224; additionally, for group M1 and M2 on day 168 as confirmed by the presence of functional anti-chikungunya antibodies as determined by the plaque reduction neutralization test (PRNT50) and by ELISA.

- please note that in the protocol the timepoint "day -28" for M1 and M2 groups is also mentioned; however that timepoint was used for testing pre-existing measles titer but has no additional value for the chikungunya-PRNTs as it would be only an additional pre-vaccination value. Please note that for some timepoints testing has not been done. "Not done" cannot be entered but only numerical values. "9999" should serve as indicator of a test which was not performed.

End point type	Secondary
----------------	-----------

## End point timeframe:

Study day 0 to day 224
------------------------

End point values	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	44	47	44
Units: Titer				
geometric mean (standard deviation)				
Day 0	5.1 (± 0.71)	5.3 (± 3.16)	5.0 (± 0.00)	5.0 (± 0.00)
Day 28	63.4 (± 10.0)	5.5 (± 3.82)	25.7 (± 52.22)	5.1 (± 0.75)
Day 168	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)
Day 196	13.5 (± 33.46)	6.4 (± 8.29)	38.8 (± 70.59)	24.1 (± 106.25)
Day 224	14.6 (± 37.87)	70.5 (± 174.57)	41.8 (± 105.55)	609.8 (± 949.70)

End point values	Treatment Group M1	Treatment Group M2	Control Group CV1, A/C	Control Group CV2, B/D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	16	15	16	16
Units: Titer				
geometric mean (standard deviation)				
Day 0	5.0 (± 0.00)	5.0 (± 0.00)	5.0 (± 0.00)	5.0 (± 0.00)
Day 28	13.5 (± 40.52)	5.0 (± 0.00)	5.0 (± 0.00)	5.0 (± 0.00)
Day 168	28.9 (± 52.25)	5.0 (± 0.00)	9999 (± 9999)	9999 (± 9999)
Day 196	24.1 (± 106.25)	11.5 (± 26.04)	5.0 (± 0.00)	5.0 (± 0.00)
Day 224	18.3 (± 87.50)	66.5 (± 172.62)	5.0 (± 0.00)	5.0 (± 0.00)

## Statistical analyses

Statistical analysis title	ANOVA to compare PRNT titers
----------------------------	------------------------------

## Statistical analysis description:

An ANOVA with the fixed factors treatment group (CV1, CV2, A, B, C, D, M1, M2) will be used to compare PRNT functional antibody geometric mean titers (GMT) per visit.

Comparison groups	Treatment Group A v Treatment Group B v Treatment Group C v Treatment Group D v Treatment Group M1 v Treatment Group M2 v Control Group CV1, A/C v Control Group CV2, B/D
Number of subjects included in analysis	247
Analysis specification	Pre-specified
Analysis type	superiority
P-value	≤ 0.05
Method	ANOVA
Parameter estimate	Mean difference (final values)
Confidence interval	
level	95 %
sides	2-sided
Variability estimate	Standard deviation

### Secondary: Shedding (Saliva)

End point title	Shedding (Saliva) <sup>[2]</sup>
End point description:	Shedding of live recombinant virus until day 196 (in a subset of subjects at one site)
End point type	Secondary
End point timeframe:	Shedding of live recombinant virus on day 0, 7, 10, 14, 28 and day 196 after the first injection

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: No statistic calculations were planned or performed - not one case of shedding was observed.

Shedding analysis relies on PCR methods amplifying measles sequences. As M1 and M2 groups receive a measles vaccination and the study vaccination (modified measles virus), a potential positive result would not be indicative of the reason and therefore these groups were not tested for shedding.

End point values	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	3	8	4
Units: Subjects shedding measles virus				
Day 0	0	0	0	0
Day 7	0	0	0	0
Day 10	0	0	0	0
Day 14	0	0	0	0
Day 28	0	0	0	0
Day 196	0	0	0	0

End point values	Control Group CV1, A/C	Control Group CV2, B/D		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	2		
Units: Subjects shedding measles virus				
Day 0	0	0		
Day 7	0	0		

Day 10	0	0		
Day 14	0	0		
Day 28	0	0		
Day 196	0	0		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Solicited Adverse Events (Safety population)

End point title	Solicited Adverse Events (Safety population)
End point description:	Number of observed AEs per treatment group.
End point type	Secondary
End point timeframe:	Throughout the study participation

End point values	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	51	47	47	50
Units: Observations				
Numer of observations	35	32	37	41

End point values	Treatment Group M1	Treatment Group M2	Control Group CV1, A/C	Control Group CV2, B/D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	16	18	16
Units: Observations				
Numer of observations	13	10	14	10

## Statistical analyses

Statistical analysis title	Fisher exact test to compare AE rates
Comparison groups	Treatment Group A v Treatment Group B v Treatment Group C v Treatment Group D v Treatment Group M1 v Treatment Group M2 v Control Group CV1, A/C v Control Group CV2, B/D

Number of subjects included in analysis	263
Analysis specification	Pre-specified
Analysis type	equivalence <sup>[3]</sup>
P-value	≤ 0.05
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Confidence interval	
level	95 %
sides	2-sided

Notes:

[3] - Pairwise comparison of treatment groups.

### Secondary: Treatment Emergent Adverse Events

End point title	Treatment Emergent Adverse Events
End point description: Observations of unsolicited treatment emergent adverse events (TEAEs).	
End point type	Secondary
End point timeframe: Throughout the study.	

<b>End point values</b>	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	51	47	47	50
Units: Observations				
TEAEs	29	27	22	18
Serious TEAEs	1	2	0	1
Severe TEAEs	1	2	0	2
Related TEAEs	8	11	4	10
Medically Attended TEAEs	12	15	9	8
TEAEs where an action was taken	0	1	0	1
TEAEs of special interest	2	2	0	1

<b>End point values</b>	Treatment Group M1	Treatment Group M2	Control Group CV1, A/C	Control Group CV2, B/D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	16	18	16
Units: Observations				
TEAEs	11	9	10	7
Serious TEAEs	0	0	1	1
Severe TEAEs	1	1	1	0
Related TEAEs	4	5	2	1
Medically Attended TEAEs	4	3	3	1
TEAEs where an action was taken	0	0	0	1
TEAEs of special interest	2	0	0	0

## Statistical analyses

<b>Statistical analysis title</b>	Fisher exact test to compare AE rates
Statistical analysis description: Pairwise comparison of TEAEs between treatment groups.	
Comparison groups	Treatment Group A v Treatment Group B v Treatment Group C v Treatment Group D v Treatment Group M1 v Treatment Group M2 v Control Group CV1, A/C v Control Group CV2, B/D
Number of subjects included in analysis	263
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	≤ 0.05
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Confidence interval	
level	95 %
sides	2-sided

## Secondary: Induction of a Chikungunya virus specific T cell response (subset of subjects)

End point title	Induction of a Chikungunya virus specific T cell response (subset of subjects)
End point description: Please note that for some timepoints testing has not been done. "Not done" cannot be entered but only numerical values. "9999" should serve as indicator of a test which was not performed.	
End point type	Secondary
End point timeframe: Study Days 0, 28, 56, and 224	

<b>End point values</b>	Treatment Group A	Treatment Group B	Treatment Group C	Treatment Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	15	12	14	11
Units: Subjects with CHIKV-specific T-cells				
Day 0	0	1	0	0
Day 28	2	9999	1	9999
Day 56	6	3	7	1
Day 224	5	4	3	3

<b>End point values</b>	Treatment Group M1	Treatment Group M2	Control Group CV1, A/C	Control Group CV2, B/D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4	5	5
Units: Subjects with CHIKV-specific T-cells				
Day 0	0	9999	0	0
Day 28	9999	9999	0	9999
Day 56	3	0	0	1
Day 224	0	0	0	1

### **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Day 0 after the first vaccination up to day 224

Adverse event reporting additional description:

Solicited and unsolicited local and systemic adverse events (AEs) were recorded throughout the study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	Treatment Group A
-----------------------	-------------------

Reporting group description:

Group A subjects received vaccinations with MVCHIK low dose on study day 0 and 28, placebo on day 196.

Reporting group title	Treatment Group B
-----------------------	-------------------

Reporting group description:

Group B subjects received vaccinations with placebo on study day 0. MV-CHIK low dose on day 28 and MV-CHIK boosting dose on day 196.

Reporting group title	Treatment Group C
-----------------------	-------------------

Reporting group description:

Group C subjects received vaccinations with MVCHIK high dose on study day 0 and 28, placebo on day 196.

Reporting group title	Treatment Group D
-----------------------	-------------------

Reporting group description:

Group D subjects received vaccinations with placebo on study day 0, MV-CHIK high dose on study day 28 and MV-CHIK boosting dose on day 196.

Reporting group title	Treatment Group M1
-----------------------	--------------------

Reporting group description:

Measles Booster Group M1 subjects received vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.

Reporting group title	Treatment Group M2
-----------------------	--------------------

Reporting group description:

Measles Booster Group M2 subjects received vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.

Reporting group title	Control Group CV1, A/C
-----------------------	------------------------

Reporting group description:

Control Group CV1, A/C subjects received vaccinations with Priorix® on study day 0 and 28, placebo on day 196.

Reporting group title	Control Group CV2, B/D
-----------------------	------------------------

Reporting group description:

Control Group CV2, B/D subjects received vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.

Serious adverse events	Treatment Group A	Treatment Group B	Treatment Group C
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 51 (1.96%)	2 / 47 (4.26%)	0 / 47 (0.00%)
number of deaths (all causes)	0	0	0

number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Laryngeal cancer	Additional description: One subject of control group CV1 experienced laryngeal cancer 5 days after receiving placebo. The subject was hospitalized and biopsy and tracheotomy were performed. The event was assessed severe in intensity and considered not related.		
subjects affected / exposed	0 / 51 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer	Additional description: One subject of group D experienced papillary thyroid cancer 4 months after receiving the first dose of MV-CHIK. The event was considered severe in intensity and not related to the study drug. Subject terminated early after Visit 3 due to this SAE.		
subjects affected / exposed	0 / 51 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications Ligament rupture	Additional description: 1 subject of group B experienced ligament rupture left knee 3 months and 12 days after receiving the first dose of MV-CHIK. The subject was hospitalized and surgery was performed. The event was considered not related to the study drug.		
subjects affected / exposed	0 / 51 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions Abortion	Additional description: 1 subject group B experienced suspected abortion 1 month and 10 days after receiving placebo. This was considered an important medical event and was judged to be mild and possibly related to the study treatment.		
subjects affected / exposed	0 / 51 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders Umbilical hernia	Additional description: 1 subject of group A experienced umbilical hernia 4 weeks after the second dose of MVCHIK. The subject was hospitalized and surgery was performed. The event was considered moderate in severity and not related to the study drug.		
subjects affected / exposed	1 / 51 (1.96%)	0 / 47 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders Type 2 diabetes mellitus	Additional description: 1 subject of control group CV2 experienced type 2 diabetes mellitus reported the same month the subject received the first dose of control vaccine. The subject was hospitalized and a diagnostic test performed. The event was assessed not related.		

subjects affected / exposed	0 / 51 (0.00%)	0 / 47 (0.00%)	0 / 47 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Treatment Group D	Treatment Group M1	Treatment Group M2
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	1 / 50 (2.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
Laryngeal cancer	Additional description: One subject of control group CV1 experienced laryngeal cancer 5 days after receiving placebo. The subject was hospitalized and biopsy and tracheotomy were performed. The event was assessed severe in intensity and considered not related.		
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer	Additional description: One subject of group D experienced papillary thyroid cancer 4 months after receiving the first dose of MV-CHIK. The event was considered severe in intensity and not related to the study drug. Subject terminated early after Visit 3 due to this SAE.		
subjects affected / exposed	1 / 50 (2.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Injury, poisoning and procedural complications</b>			
Ligament rupture	Additional description: 1 subject of group B experienced ligament rupture left knee 3 months and 12 days after receiving the first dose of MV-CHIK. The subject was hospitalized and surgery was performed. The event was considered not related to the study drug.		
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pregnancy, puerperium and perinatal conditions</b>			
Abortion	Additional description: 1 subject group B experienced suspected abortion 1 month and 10 days after receiving placebo. This was considered an important medical event and was judged to be mild and possibly related to the study treatment.		
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			

Umbilical hernia	Additional description: 1 subject of group A experienced umbilical hernia 4 weeks after the second dose of MVCHIK. The subject was hospitalized and surgery was performed. The event was considered moderate in severity and not related to the study drug.		
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Type 2 diabetes mellitus	Additional description: 1 subject of control group CV2 experienced type 2 diabetes mellitus reported the same month the subject received the first dose of control vaccine. The subject was hospitalized and a diagnostic test performed. The event was assessed not related.		
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Control Group CV1, A/C	Control Group CV2, B/D	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 18 (5.56%)	1 / 16 (6.25%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Laryngeal cancer	Additional description: One subject of control group CV1 experienced laryngeal cancer 5 days after receiving placebo. The subject was hospitalized and biopsy and tracheotomy were performed. The event was assessed severe in intensity and considered not related.		
subjects affected / exposed	1 / 18 (5.56%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer	Additional description: One subject of group D experienced papillary thyroid cancer 4 months after receiving the first dose of MV-CHIK. The event was considered severe in intensity and not related to the study drug. Subject terminated early after Visit 3 due to this SAE.		
subjects affected / exposed	0 / 18 (0.00%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ligament rupture	Additional description: 1 subject of group B experienced ligament rupture left knee 3 months and 12 days after receiving the first dose of MV-CHIK. The subject was hospitalized and surgery was performed. The event was considered not related to the study drug.		
subjects affected / exposed	0 / 18 (0.00%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Pregnancy, puerperium and perinatal conditions			
Abortion	Additional description: 1 subject group B experienced suspected abortion 1 month and 10 days after receiving placebo. This was considered an important medical event and was judged to be mild and possibly related to the study treatment.		
subjects affected / exposed	0 / 18 (0.00%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Umbilical hernia	Additional description: 1 subject of group A experienced umbilical hernia 4 weeks after the second dose of MVCHIK. The subject was hospitalized and surgery was performed. The event was considered moderate in severity and not related to the study drug.		
subjects affected / exposed	0 / 18 (0.00%)	0 / 16 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Type 2 diabetes mellitus	Additional description: 1 subject of control group CV2 experienced type 2 diabetes mellitus reported the same month the subject received the first dose of control vaccine. The subject was hospitalized and a diagnostic test performed. The event was assessed not related.		
subjects affected / exposed	0 / 18 (0.00%)	1 / 16 (6.25%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Treatment Group A	Treatment Group B	Treatment Group C
Total subjects affected by non-serious adverse events			
subjects affected / exposed	42 / 51 (82.35%)	39 / 47 (82.98%)	39 / 47 (82.98%)
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 51 (0.00%)	1 / 47 (2.13%)	0 / 47 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Influenza like illness			
subjects affected / exposed	1 / 51 (1.96%)	0 / 47 (0.00%)	1 / 47 (2.13%)
occurrences (all)	1	0	1
Fatigue			
subjects affected / exposed	2 / 51 (3.92%)	1 / 47 (2.13%)	0 / 47 (0.00%)
occurrences (all)	2	1	0
Axillary pain			

subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 47 (2.13%) 1	0 / 47 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 2	1 / 47 (2.13%) 3	1 / 47 (2.13%) 2
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)  Cough subjects affected / exposed occurrences (all)  Dyspnoea subjects affected / exposed occurrences (all)  Sneezing subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1  1 / 51 (1.96%) 1  0 / 51 (0.00%) 0  0 / 51 (0.00%) 0	1 / 47 (2.13%) 1  2 / 47 (4.26%) 2  0 / 47 (0.00%) 0  0 / 47 (0.00%) 0	4 / 47 (8.51%) 5  1 / 47 (2.13%) 1  1 / 47 (2.13%) 1  0 / 47 (0.00%) 0
Injury, poisoning and procedural complications Injury subjects affected / exposed occurrences (all)  Skin abrasion subjects affected / exposed occurrences (all)  Contusion subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0  0 / 51 (0.00%) 0  0 / 51 (0.00%) 0	0 / 47 (0.00%) 0  0 / 47 (0.00%) 0  0 / 47 (0.00%) 0	1 / 47 (2.13%) 1  0 / 47 (0.00%) 0  0 / 47 (0.00%) 0
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	7 / 51 (13.73%) 8	2 / 47 (4.26%) 2	1 / 47 (2.13%) 1
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)  Vertigo subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0  0 / 51 (0.00%) 0	0 / 47 (0.00%) 0  0 / 47 (0.00%) 0	1 / 47 (2.13%) 1  0 / 47 (0.00%) 0
Eye disorders Dry eye subjects affected / exposed occurrences (all)  Eye pruritus subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0  0 / 51 (0.00%) 0	0 / 47 (0.00%) 0  0 / 47 (0.00%) 0	0 / 47 (0.00%) 0  0 / 47 (0.00%) 0
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Abdominal pain subjects affected / exposed occurrences (all)  Toothache subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1  1 / 51 (1.96%) 1	0 / 47 (0.00%) 0  1 / 47 (2.13%) 1  1 / 47 (2.13%) 1  0 / 47 (0.00%) 0	2 / 47 (4.26%) 2  0 / 47 (0.00%) 0  0 / 47 (0.00%) 0  0 / 47 (0.00%) 0
Skin and subcutaneous tissue disorders Dermatitis contact			

subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Rash subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 47 (2.13%) 1	0 / 47 (0.00%) 0
Erythema multiforme subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Renal and urinary disorders Hypertonic bladder subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	2 / 47 (4.26%) 2	2 / 47 (4.26%) 3
Myalgia subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	2 / 47 (4.26%) 2	0 / 47 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	1 / 47 (2.13%) 1	0 / 47 (0.00%) 0
Bursitis subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	7 / 51 (13.73%) 7	4 / 47 (8.51%) 4	4 / 47 (8.51%) 5
Rhinitis subjects affected / exposed occurrences (all)	2 / 51 (3.92%) 2	0 / 47 (0.00%) 0	3 / 47 (6.38%) 3
Upper respiratory tract infection			

subjects affected / exposed occurrences (all)	3 / 51 (5.88%) 3	3 / 47 (6.38%) 4	1 / 47 (2.13%) 2
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	1 / 47 (2.13%) 1	1 / 47 (2.13%) 1
Gingivitis subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Vaginal infection subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0
Metabolism and nutrition disorders Appetite disorder subjects affected / exposed occurrences (all)	0 / 51 (0.00%) 0	0 / 47 (0.00%) 0	0 / 47 (0.00%) 0

<b>Non-serious adverse events</b>	Treatment Group D	Treatment Group M1	Treatment Group M2
Total subjects affected by non-serious adverse events subjects affected / exposed	42 / 50 (84.00%)	15 / 18 (83.33%)	14 / 16 (87.50%)
Vascular disorders Haematoma subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
General disorders and administration site conditions Influenza like illness subjects affected / exposed occurrences (all)	3 / 50 (6.00%) 3	1 / 18 (5.56%) 1	1 / 16 (6.25%) 1
Fatigue			

subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
Axillary pain subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 2	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 8	2 / 18 (11.11%) 4	1 / 16 (6.25%) 1
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	2 / 18 (11.11%) 3	1 / 16 (6.25%) 1
Cough subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	1 / 16 (6.25%) 1
Dyspnoea subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Sneezing subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Injury, poisoning and procedural complications Injury subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Skin abrasion subjects affected / exposed occurrences (all)	1 / 50 (2.00%) 1	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Contusion			

subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	4 / 50 (8.00%) 9	1 / 18 (5.56%) 1	2 / 16 (12.50%) 2
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)  Vertigo subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0  0 / 50 (0.00%) 0	1 / 18 (5.56%) 1  0 / 18 (0.00%) 0	0 / 16 (0.00%) 0  2 / 16 (12.50%) 2
Eye disorders Dry eye subjects affected / exposed occurrences (all)  Eye pruritus subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0  0 / 50 (0.00%) 0	0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	1 / 16 (6.25%) 1  1 / 16 (6.25%) 1
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)  Diarrhoea subjects affected / exposed occurrences (all)  Abdominal pain subjects affected / exposed occurrences (all)  Toothache subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0  1 / 50 (2.00%) 1  0 / 50 (0.00%) 0  1 / 50 (2.00%) 1	0 / 18 (0.00%) 0  1 / 18 (5.56%) 1  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0  1 / 16 (6.25%) 1  1 / 16 (6.25%) 1

Skin and subcutaneous tissue disorders			
Dermatitis contact			
subjects affected / exposed	1 / 50 (2.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	1 / 50 (2.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	1	1	0
Erythema multiforme			
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Hypertonic bladder			
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 50 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	4	0
Musculoskeletal pain			
subjects affected / exposed	0 / 50 (0.00%)	0 / 18 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Bursitis			
subjects affected / exposed	0 / 50 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			
subjects affected / exposed	0 / 50 (0.00%)	1 / 18 (5.56%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 50 (8.00%)	2 / 18 (11.11%)	1 / 16 (6.25%)
occurrences (all)	5	5	1
Rhinitis			

subjects affected / exposed occurrences (all)	2 / 50 (4.00%) 2	2 / 18 (11.11%) 3	2 / 16 (12.50%) 2
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0
Gingivitis subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 0
Hordeolum subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Respiratory tract infection subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0
Vaginal infection subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1
Metabolism and nutrition disorders Appetite disorder subjects affected / exposed occurrences (all)	0 / 50 (0.00%) 0	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0

<b>Non-serious adverse events</b>	Control Group CV1, A/C	Control Group CV2, B/D	
Total subjects affected by non-serious adverse events subjects affected / exposed	14 / 18 (77.78%)	12 / 16 (75.00%)	
Vascular disorders Haematoma subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
General disorders and administration site conditions			

Influenza like illness subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Fatigue subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Axillary pain subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 16 (6.25%) 1	
Cough subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Sneezing subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Injury, poisoning and procedural complications Injury subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1	
Skin abrasion			

subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Contusion subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2	1 / 16 (6.25%) 1	
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Vertigo subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Eye disorders Dry eye subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Eye pruritus subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 16 (6.25%) 1	
Diarrhoea subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Abdominal pain subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	

Toothache subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Skin and subcutaneous tissue disorders Dermatitis contact subjects affected / exposed occurrences (all)  Rash subjects affected / exposed occurrences (all)  Erythema multiforme subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0  0 / 16 (0.00%) 0	
Renal and urinary disorders Hypertonic bladder subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)  Myalgia subjects affected / exposed occurrences (all)  Musculoskeletal pain subjects affected / exposed occurrences (all)  Bursitis subjects affected / exposed occurrences (all)  Muscle spasms subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0  0 / 18 (0.00%) 0  1 / 18 (5.56%) 1  0 / 18 (0.00%) 0  0 / 18 (0.00%) 0	1 / 16 (6.25%) 1  1 / 16 (6.25%) 1  0 / 16 (0.00%) 0  0 / 16 (0.00%) 0  0 / 16 (0.00%) 0	
Infections and infestations Nasopharyngitis			

subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2	2 / 16 (12.50%) 3	
Rhinitis			
subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Upper respiratory tract infection			
subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Urinary tract infection			
subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 16 (0.00%) 0	
Gingivitis			
subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Hordeolum			
subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Respiratory tract infection			
subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Vaginal infection			
subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Vulvovaginal candidiasis			
subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	
Metabolism and nutrition disorders			
Appetite disorder			
subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 16 (0.00%) 0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 August 2016	<p>Protocol Amendment 1 (substantial, dated 26-Apr-2016) incorporated in Protocol version 1.3 (26-Apr-2016) before the first study submission.</p> <p>The protocol was amended:</p> <ul style="list-style-type: none"><li>To precisely define the primary endpoint as immunogenicity on Day 56 for all treatment groups</li><li>To adapt the study design (by shifting study visits) to enable immunogenicity measurements on Day 56 for all treatment groups</li><li>To change the definition from three cohorts consisting of two different treatment regimens each, to a more reasonable definition of six treatment groups</li><li>To define the dates of study visits based on an interval of 28 days and to rename the study days as follows: Screening Visit on Study Day -35; Visit 0 on Study Day -28; Visit 1 on Study Day 0; Visit 2 on Study Day 28; Visit 3 on Study Day 56; Visit 4 on Study Day 168; Visit 5 on Study Day 196; Visit 6 on Study Day 224</li><li>To state the study objectives more precisely</li><li>To include a preliminary data analysis</li><li>To describe the role of the DSMB</li><li>To remove the safety assessment by telephone call, 12 months after the first vaccination</li><li>To clarify that the control-vaccine Priorix® can be exchanged by MMR-Vax-Pro® or equal measles vaccine</li></ul> <p>In addition, to correct typos, include some formal changes and update the list of abbreviations</p>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported